CVM Orders Centaurus to Launch R$6 Billion OPA for Oncoclínicas
The collegiate decision compels a payment market sources place above R$6 billion while Centaurus has opened an arbitration case at B3’s CAM to contest the obligation.
Overview
- The CVM collegiate voted unanimously to require Centaurus’s Josephina III fund to carry out a mandatory offer for Oncoclínicas following a board hearing on Tuesday, reversing the regulator’s technical recommendation.
- The demand for an offer stems from a poison‑pill clause in Oncoclínicas’ bylaws that triggers an OPA when a shareholder exceeds 15% after a November 2024 reorganization tied to Goldman Sachs put Centaurus over that threshold.
- CVM technical staff had twice recommended denying the OPA, saying the November 2024 reorganization fit a statutory exception and left Centaurus with economic exposure rather than titular rights, a view the collegiate rejected.
- Centaurus preemptively filed an arbitration claim at B3’s Câmara de Arbitragem do Mercado before the CVM vote and said it will rely on that forum to resolve the dispute, so the case is likely to proceed in parallel across arbitration and possible court review.
- The decision raises immediate financial stakes for Oncoclínicas’ creditors and minority shareholders because the required offer is far above current market prices and will interact with the company’s ongoing extrajudicial recovery process that lists R$5.1 billion in liabilities.